Women and Finasteride: The Off-Label Evidence You Won't Find on the Label
Off-Label, Not Off-Limits
Finasteride is FDA-approved only for men. But it's prescribed off-label for postmenopausal women with female pattern hair loss (FPHL) — and a 2025 Clinical Dermatology review showed meaningful improvement in hair density at higher doses (2–5mg).
| Factor | Men | Postmenopausal Women |
|---|---|---|
| FDA-approved? | Yes (1mg) | No (off-label) |
| Typical dose | 1mg daily | 2–5mg daily |
| Evidence | 30+ years of RCTs | Growing — 2025 review positive |
| Pregnancy concern | Category X for female partners | N/A (postmenopausal) |
| First-line treatment | Yes | No — minoxidil + spironolactone first |
Sesame Care
BRAND-NAME ONLYConnect with a provider experienced in female pattern hair loss.
Discuss Women's Hair Loss →Frequently Asked Questions
Why isn't finasteride approved for women?
Merck never sought FDA approval for women due to the pregnancy risk and smaller market. The off-label evidence has accumulated independently through academic research.
What about women of childbearing age?
Finasteride can only be considered with highly reliable contraception AND informed consent about teratogenic risk. Most providers restrict it to postmenopausal women.
How effective is finasteride for women?
The 2025 review showed meaningful improvement in hair density at 2–5mg doses in postmenopausal women with FPHL. Effect sizes may be smaller than in men due to differences in hair loss pathophysiology.